Early prostate cancer study explores new drug combination approach
NCT ID NCT03507608
Summary
This early study tested whether adding a single dose of the drug flutamide to standard prostate cancer treatment (hormone therapy plus radiation seeds) causes DNA damage in cancer cells. Researchers enrolled 25 men with prostate cancer who were already scheduled to receive standard treatment. The goal was to see if this drug combination approach might make cancer cells more vulnerable to treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
SKCCC at Johns Hopkins
Baltimore, Maryland, 21287, United States
Conditions
Explore the condition pages connected to this study.